SMMT News and Press, Summit Therapeutics Inc. From 05/24/24

2024-05-24 07:45:37 ET More on Akeso, Summit Therapeutics, etc. Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript ...

2024-05-08 13:30:06 ET Summary NPMA decision on whether to approve Summit Therapeutics Inc.'s ivonescimab for the treatment of patients with EGFR-mutant metastatic non-squamous NSCLC following TKI progression is expected in Q2 of 2024. Interim analysis from phase 2 AK112-303 study...

2024-05-07 13:56:20 ET More on Summit Therapeutics Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript ...

2024-05-07 07:15:07 ET Citigroup analyst issues BUY recommendation for SMMT on May 7, 2024 05:12AM ET. SMMT was trading at $4.47 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations

2024-05-06 11:02:30 ET Summary Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases. Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows promise in treating non-small cell lung cancer. ...

2024-05-01 22:00:06 ET Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Conference Call May 01, 2024, 09:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and Chief Executive Officer Maky Zanganeh ...

2024-05-01 07:12:22 ET More on Summit Therapeutics Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript Summit Therapeutics stock plunges 28% amid financial updates Seeking Alpha’s Quant Rating on Summit Therapeutics Historical earnings dat...

HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSC...

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company ...